Repository logo
 
Publication

Correction: The meaning of lymphadenopathies during adjuvant durvalumab after chemoradiotherapy for lung cancer: thinking beyond disease progression

2023-02Journal article Open access
Simple item page
dc.contributor.authorPantarotto, Marcos
dc.contributor.authorBarata, Rita
dc.contributor.authorCoelho, Ricardo
dc.contributor.authorSousa, Virginia
dc.contributor.authorCarvalheiro, Catarina
dc.contributor.authorRolim, Ines
dc.contributor.authorGarrido, Patricia
dc.contributor.authorGIl, Nuno
dc.contributor.authorDuarte-Ramos, Filipa
dc.contributor.authorTonin, Fernanda
dc.date.accessioned2023-02-28T15:40:50Z
dc.date.available2023-02-28T15:40:50Z
dc.date.issued2023-02
dc.description.abstractThis article has been corrected at the request of the authors to include Virginia Sousa as the fourth author as she was erroneously omitted during the submission process. The authors deeply regret that this error was not identified and addressed prior to publication.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationPantarotto M, Barata R, Coelho R, Cavalheiro C, Rolim I, Tonin FS, et al. Correction: The meaning of lymphadenopathies during adjuvant durvalumab after chemoradiotherapy for lung cancer: thinking beyond disease progression. Cureus. 2023;15(2):c101.pt_PT
dc.identifier.doi10.7759/cureus.c101pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.21/15726
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherSpringer Naturept_PT
dc.relation.publisherversionhttps://www.cureus.com/articles/98971-the-meaning-of-lymphadenopathies-during-adjuvant-durvalumab-after-chemoradiotherapy-for-lung-cancer-thinking-beyond-disease-progression/correction/166#!/pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.subjectImmune-checkpoint inhibitorspt_PT
dc.subjectPseudoprogressionpt_PT
dc.subjectImmune-related adverse eventspt_PT
dc.subjectLung cancerpt_PT
dc.subjectDifferential diagnosispt_PT
dc.titleCorrection: The meaning of lymphadenopathies during adjuvant durvalumab after chemoradiotherapy for lung cancer: thinking beyond disease progressionpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue2pt_PT
oaire.citation.startPagec101pt_PT
oaire.citation.titleCureuspt_PT
oaire.citation.volume15pt_PT
person.familyNameTonin
person.givenNameFernanda
person.identifier.ciencia-idD01C-C700-9411
person.identifier.orcid0000-0003-4262-8608
person.identifier.ridO-2050-2017
person.identifier.scopus-author-id56085115800
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication61ded30e-ecec-4b3e-b953-2293e080ebdd
relation.isAuthorOfPublication.latestForDiscovery61ded30e-ecec-4b3e-b953-2293e080ebdd

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Correction_The meaning of lymphadenopathies during adjuvant durvalumab after chemoradiotherapy for lung cancer_thinking beyond disease progression.pdf
Size:
46.38 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESTeSL - Artigos